Martin Pöhlchen, PhD
Partner, Munich, Germany
Dr. Martin Pöhlchen obtained a PhD in chemistry and was actively involved in the development or commercialisation of several NCEs, protein scaffolds, cell and gene therapy vaccines and platforms, e.g. in the AAV, CVLP and the HSV oncoloytic virus area. He has over 20 years of experience in general management, licensing, business & corporate development, sales & marketing, private & public corporate finance, strategic transactions, mergers and acquisitions, intellectual property and R&D management, including drug & regulatory development. Among his professional experience are roles as Co-founder at Sinfonie Life Science Management GmbH, CEO of Pieris and Revotar, Vice President BD at MediGene and European Commercial Director at Tripos (now Certara). He has advised on transactions exceeding €0.5 bn in total value. In 2004 he was honored as one of the finalists of the “Deutscher Zukunftspreis”, the Federal President’s award for technology and innovation.